# Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)

> **NCT03391973** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AHS Cancer Control Alberta** · enrollment: 26 (actual)

## Conditions studied

- Carcinoma of Unknown Primary

## Interventions

- **DRUG:** Pembrolizumab Injection

## Key facts

- **NCT ID:** NCT03391973
- **Lead sponsor:** AHS Cancer Control Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-24
- **Primary completion:** 2023-06-16
- **Final completion:** 2025-12-30
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2025-04-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03391973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03391973, "Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03391973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*